Skip to main
IRTC

iRhythm Technologies (IRTC) Stock Forecast & Price Target

iRhythm Technologies (IRTC) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 42%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

iRhythm Technologies has provided an optimistic outlook for 2025, with revenue guidance raised to $735M-$740M, reflecting a year-over-year growth rate of 24.6% at the midpoint, above previous estimates. The company reported an adjusted gross margin of 71.1%, marking a 230 basis point increase year-over-year and surpassing consensus expectations, which bolsters its financial health. Additionally, iRhythm continues to expand its presence internationally, particularly in Japan and the UK private market, indicating sustained growth potential driven by its core business and innovative product offerings.

Bears say

The excerpts indicate a negative outlook for iRhythm Technologies due to a forecasted slowing growth rate, projected at the low-teens, alongside concerns regarding profitability. Significant risks include regulatory scrutiny from the Department of Justice and the FDA, which could adversely affect operations and financial results, as well as heightened competition that could diminish commercial opportunities. Additionally, the company's reliance on physician adoption of its Zio service and a history of net losses further contribute to the challenges it faces in achieving sustainable profitability amidst a competitive market landscape.

iRhythm Technologies (IRTC) has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 42% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iRhythm Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iRhythm Technologies (IRTC) Forecast

Analysts have given iRhythm Technologies (IRTC) a Buy based on their latest research and market trends.

According to 12 analysts, iRhythm Technologies (IRTC) has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $215.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $215.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iRhythm Technologies (IRTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.